Synthesis, antitubercular activity and docking study of novel cyclic azole substituted diphenyl ether derivatives

European Journal of Medicinal Chemistry

Volumn 44, Issue 2, 2009, Pages 492-500

  Kini, Suvarna G ^a   Bhat, Anilchandra R ^b   Bryant, Byron ^c   Williamson, John S ^c   Dayan, Franck E ^d  

^a MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

^b KLE's Institute of Dental Sciences   (India)

^c UNIVERSITY OF MISSISSIPPI   (United States)

^d NATURAL PRODUCTS UTILIZATION RESEARCH UNIT   (United States)

Author keywords

Antitubercular activity; Docking; Enoyl ACP reductase; Tuberculosis

Indexed keywords

DIPHENYL ETHER DERIVATIVE; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH); ISONIAZID; PYRROLE DERIVATIVE; RIFAMPICIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; MOLECULAR DOCKING; MOLECULAR MODEL; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REACTION ANALYSIS; STRUCTURE ANALYSIS;

ANTITUBERCULAR AGENTS; AZOLES; BINDING SITES; COMPUTER SIMULATION; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MYCOBACTERIUM; PHENYL ETHERS; PROTEIN BINDING;

EID: 60149091036     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2008.04.013     Document Type: Article

References (52)

1. Wolinsky E. In: Wyangaarden J.B., Smith Jr. L.H., and Bennett J.C. (Eds). Tuberculosis. 19th ed. Cecil Textbook of Medicine vol. 2 (1992), W.B. Saunders Company, Philadelphia, PA 1733-1742
2. Sensi P., and Grass I.G.G. In: Burger A., and Wolff M.E. (Eds). Antimycobacterial Agents. fifth ed. Burger's Medicinal Chemistry and Drug Discovery vol. 2 (1996), John Wiley & Sons, New York 575-635
3. Bloom B.R., and Murray C.J.L. Tuberculosis: commentary on a reemergent killer. Science 257 (1992) 1055-1064
4. Okada M., and Kobayashi K. Recent progress in mycobacteriology. Kekkaku (Japanese Journal) 82 10 (2007) 783-799
5. World Health Organization Report on TB epidemic, Global TB Programme, World Health Oraganization, Geneva, 1997.
6. World Health Organisation, Tuberculosis, Fact Sheet No. 104, 2007 (site accessed: ).
7. ElSayed K.A., Bartyzel P., Shen X.Y., Perry T.L., Zjawiony J.K., and Hamann M.T. Marine natural products as antituberculosis agents. Tetrahedron 56 (2000) 949-953
8. Goldberg M.J. Antituberculosis agents. Med. Clin. North. Am. 72 (1988) 661-668
9. Tomioka H., and Namba K. Development of antitubercular drugs: current status and future prospects. Kekkaku (Japanese Journal) 81 12 (2006) 753-774
10. Berning S.E. The role of fluoroquinolones in tuberculosis today. Drugs 61 (2001) 9-18
11. Reddy V.M., Nadadhur G., Daneluzzi D.D., Osullivan J.F., and Gangadharam P.R.J. Antituberculosis activities of clofazimine and its new analogs B4154 and B4157. Antimicrob. Agents Chemother. 40 (1996) 633-636
12. Barry C.E. New horizons in the treatment of tuberculosis. Biochem. Pharmacol. 54 (1997) 1165-1172
13. Pasquato K.F.M., and Ferreira E.I. An approach for the rational design of new antitubercular agents. Curr. Drug Targets 2 (2001) 427-437
14. Schroeder E.K., de Souza N., Santos D.D., Blanchard J.S., and Basso L.A. Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis. Curr. Pharm. Biotechnol. 3 3 (2002) 197-225
15. Barry III C.E., Lee R.E., Mdluli K., Sampson A.E., Schroeder B.G., Slayden R.A., and Yaun Y. Mycolic acid structure, biosynthesis and physiological functions. Prog. Lipid Res. 37 (1998) 143-179
16. Kolattukudy P.E., Fernandes N.D., Azad A.K., Fitzmaurice A.M., and Sirakova T.D. Biochemistry and molecular genetics of cell-wall lipid biosynthesis in mycobacteria. Mol. Microbiol. 24 (1997) 263-270
17. Bergler H., Fuchsbichler S., Hogenauer G., and Turnowsky F. The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA. Eur. J. Biochem. 242 (1996) 689-694
18. Stewart M.J., Parikh S., Xiao G., Tonge P.J., and Kisker C. Structural basis and mechanism of enoyl reductase inhibition by triclosan. J. Mol. Biol. 290 (1999) 859-865
19. + and a C16 fatty substrate. J. Biol. Chem. 274 (1999) 15582-15589
20. Boshoff H.I., Mizrahi V., and Barry III C.E. Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. J. Bacteriol. 184 (2002) 2167-2172
21. Zimhony O., Cox J.S., Welch J.T., Vilcheze C., and Jacobs Jr. W.R. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat. Med. 6 (2000) 1043-1047
22. Schweizer H.P. Triclosan: a widely used biocide and its link to antibiotics. FEMS Microbiol. Lett. 202 (2001) 1-7
23. Regos J., Zak O., Solf R., Vischer W.A., and Weirich E.G. Antimicrobial spectrum of triclosan, a broad-spectrum antimicrobial agent for topical application. II. Comparison with some other antimicrobial agents. Dermatologica 1158 (1979) 72-79
24. Vischer W.A., and Regos J. Antimicrobial spectrum of triclosan, a broad-spectrum antimicrobial agent for topical application. Zentralbl. Bakteriol. [Orig A] 226 (1974) 376-389
25. McMurry L.M., Oethinger M., and Levy S.B. Triclosan targets lipid synthesis. Nature 394 (1998) 531-532
26. Heath R.J., Yu Y.T., Shapiro M.A., Olson E., and Rock C.O. Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis. J. Biol. Chem. 273 (1998) 30316-30320
27. Levy C.W., Roujeinikova A., Sedelnikova S., Baker P.J., and Stuitje A.R. Molecular basis of triclosan activity. Nature 398 (1999) 383-384
28. Roujeinikova A., Levy C.W., Rowsell S., Sedelnikova S., Baker P.J., Minshull C.A., Mistry A., Colls J.G., Camble R., Stuitje A.R., Slabas A.R., Rafferty J.B., Pauptit R.A., Viner R., and Rice D.W. Crystallographic analysis of triclosan bound to enoyl reductase. J. Mol. Biol. 294 (1999) 527-535
29. Heath R.J., Li J., Roland G.E., and Rock C.O. Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene. J. Biol. Chem. 275 (2001) 4654-4659
30. Marcinkeviciene J., Jiang W., Kopcho L.M., Locke G., and Luo Y. Enoyl-ACP reductase (FabI) of Haemophilus influenzae: steady-state kinetic mechanism and inhibition by triclosan and hexachlorophene. Arch. Biochem. Biophys. 390 (2001) 101-108
31. McMurry L.M., McDermott P.F., and Levy S.B. Genetic evidence that InhA of Mycobacterium smegmatis is a target for triclosan. Antimicrob. Agents Chemother. 43 (1999) 711-713
32. Parikh S.L., Xiao G., and Tonge P.J. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. Biochemistry 39 (2000) 7645-7650
33. Kuo M.R., Morbidoni H.R., Alland D., Sneddon S.F., and Gourlie B.B. Targeting tuberculosis and malaria through inhibition of enoyl reductase: compound activity and structural data. J. Biol. Chem. 278 (2003) 20851-20859
34. Surolia N., and Surolia A. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nat. Med. 7 (2001) 167-173
35. Kapoor M., Dar M.J., Surolia N., and Surolia A. Kinetic determinants of the interaction of enoyl-ACP reductase from Plasmodium falciparum with its substrates and inhibitors. Biochem. Biophys. Res. Commun. 289 (2001) 832-837
36. Perozzo R., Kuo M., bir Singh Sidhu A., Valiyaveettil J.T., Bittman R., Jacobs Jr. W.R., Fidock D.A., and Sacchettini J.C. Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl ACP reductase. J. Biol. Chem. 277 (2002) 13106
37. Vincent C.B., and Twomey D. Derivatives of diploicin. Proc. Royal Irish Acad. 53B (1950) 55-59
38. Dosages and Pharmacokinetics of Antituberculosis medications - A Report in India, 13.06.2006 (site accessed: ).
39. Qiu X., Janson C.A., Court R.I., Smyth M.G., Payne D.J., and Abdel-Meguid S.S. Molecular basis for triclosan activity involves a flipping loop in the active site. Protein Sci. 8 (1999) 2529-2532
40. Rarey M., Kramer B., Lengauer T., and Klebe G.A. Fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 261 (1996) 470-489
41. Kramer B., Rarey M., and Lengauer T. Evaluation of the FlexX incremental construction algorithm for protein-ligand docking. Proteins: structure, function, and genetics. J. Mol. Biol. 37 (1999) 228-241
42. Bissantz C., Folkers G., and Rognan D. Protein-based virtual screening of chemical databases. Part 1. Evaluation of different docking/scoring combinations. J. Med. Chem. 43 (2000) 4759-4767
43. Heath R.J., Rubin J.R., Holland D.R., Zhang E., Snow M.E., and Rock C.O. Mechanism of triclosan inhibition of bacterial fatty acid synthesis. J. Biol. Chem. 274 (1999) 11110-11114
44. Sivarana S., Sullivan T.J., Johnson F., Novichenok P., Cui G., Simmerling C., and Tonge P.J. Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues. J. Med. Chem. 47 (2004) 509-518
45. Furniss B.S., Hannaford A.J., Rogers V., Smith P.W.G., and Tatchell A.R. Aromatic carboxylic acids. Vogel's Text Book of Practical Organic Chemistry. fourth ed. (1980), Longman Group Limited, London p. 824
46. R. Udupi, Studies on the Synthesis of Substituted Triazoles, Azetidinones, Quinazolinones and Related Compounds for Possible Antitubercular Activity and other Pharmacological Profiles, Ph.D. Thesis, 1995.
47. Watt B., Rayner A., Harris G., Mackie, and McCartney. In: Colle J.G., Fraser A.G., Marmion B.P., and Simmons A. (Eds). Practical Medical Microbiology (1996), Churchill Livingstone, New York 331-335 (Chapter18)
48. Edsall J.T., Flory P.J., Kendrew J.C., Liquori A.M., Nemethy G., Ramachandran G.N., and Scheraga H.A. A proposal of standard conventions and nomenclature for the description of polypeptide conformations. J. Biol. Chem. 241 (1966) 1004-1008
49. Purcell W., and Singer J.A. Brief review and table of semiempirical parameters used in the Hueckel molecular orbital method. J. Chem. Eng. Data. 12 (1967) 235-246
50. Cieplak P., Cornell W.D., Bayly C., and Kollman P.A. Application of the multimolecule and multiconformational RESP methodology to biopolymers: charge derivation for DNA, RNA, and proteins. J. Comput. Chem. 16 (1995) 1357-1377
51. Leach A.R., and Kuntz I. Conformational analysis of flexible ligands in macromolecular receptor sites. J. Comput. Chem. 13 (1992) 730-748
52. Rarey M., Kramer B., and Lengauer T. Multiple automatic base selection: protein-ligand docking based on incremental construction without manual intervention. J. Comput.-Aided Mol. Des. 11 (1997) 369-384